500 days to Dakar 2026: a bold celebration of youth, sport and African identity
18 June 2025 – A powerful new video, street art campaigns and…
Hyundai Motor Group Announces Grand Prix Recipient and Exhibitions of the 6th VH AWARD
Hyundai Motor Group premieres five commissioned artworks of the 6th VH AWARD…
“AI and the Art Market” by Arte, with Artprice by Artmarket and analysis by Perplexity.AI Labs
PARIS, June 16, 2025 /PRNewswire/ -- This Sunday, June 15th, 2025, the…
XPPen Partners with Annecy International Animation Film Festival to Launch the Inaugural XPPen Award for Graduation Films, Nurturing the Next-Gen Talent
LOS ANGELES, June 16, 2025 /PRNewswire/ -- XPPen, the leading digital art…
Pioneering Sustainable Solutions: The Art of Living’s 4R Approach
BENGALURU, India, June 13, 2025 /PRNewswire/ -- Water, the elixir of life,…
Dazu Rock Carvings: The Last Monument of World Grotto Art
CHONGQING, China, June 12, 2025 /PRNewswire/ -- Located in southwest China's Chongqing…
Metamorphoses | 2025 CAA Graduation Season
HANGZHOU, China, June 10, 2025 /PRNewswire/ -- As 2025 approaches its most…
AUTOMOBILI PININFARINA UNVEILS ONE-OF-A-KIND BATTISTA NOVANTACINQUE TO CELEBRATE 95 YEARS OF ICONIC DESIGN
Automobili Pininfarina has unveiled the Battista Novantacinque, a bespoke model created as…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…